Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results

Go back to Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results

Arrowhead Research (ARWR) PT Raised to $18 at Cantor Fitzgerald

August 8, 2018 6:58 AM EDT

Cantor Fitzgerald raised its price target on Arrowhead Research (NASDAQ: ARWR) to $18.00 (from $13.00) while maintaining a Overweight rating following 3Q18 financial and corporate updates.

Analyst Elemer Piros commented, "The company hosted a call and highlighted upcoming data presentations at AASLD (pending abstract... More

Arrowhead Research (ARWR) PT Raised to $17.50 at Chardan Capital Markets

August 8, 2018 6:55 AM EDT

Chardan Capital Markets raised its price target on Arrowhead Research (NASDAQ: ARWR) to $17.50 (from $16.00) while maintaining a Buy rating.

... More

Arrowhead Pharmaceuticals Corp (ARWR) Reports In-Line Q3 EPS, Revenues Beat

August 7, 2018 4:00 PM EDT

Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q3 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $727.38 thousand versus the consensus estimate of $690 thousand.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.

... More